Primary drug used in chronic management of mania in bipolar disorder.

Lithium is a narrow therapeutic index mood stabilizer commonly used in the treatment of bipolar disorder. Early in therapy, patients may experience mild gastrointestinal side effects such as nausea, abdominal discomfort, and bloating as the body adjusts to the medication. Therapeutic levels must be carefully monitored because toxicity can occur with small increases in serum concentration. Clinical decisions are guided by serum levels, symptom severity, and signs of toxicity.

Rationale:
A. Contacting the prescriber to request serum electrolytes is not the priority because lithium therapy is already being appropriately monitored with a therapeutic level provided. While electrolytes may be assessed in some situations, mild gastrointestinal side effects without toxicity do not warrant immediate additional lab testing.

B. Administering the dose and reassuring the patient is appropriate because a lithium level of 0.8 mEq/L is within the therapeutic range (generally 0.6–1.2 mEq/L for maintenance). Mild nausea and abdominal bloating are common early side effects that typically improve with continued therapy. Taking the medication with food or adjusting timing can also help reduce gastrointestinal discomfort.

C. Requesting an order for amiloride (Midamor) is not indicated in this situation. Amiloride is sometimes used in lithium management to reduce renal lithium reabsorption in specific cases of toxicity or nephrogenic diabetes insipidus. The patient has a therapeutic level and only mild expected side effects, so this intervention is unnecessary.

D. Holding the dose and notifying the prescriber is inappropriate because there are no signs of lithium toxicity and the serum level is within therapeutic range. Toxicity would present with symptoms such as coarse tremors, confusion, vomiting, or ataxia, which are not present here. Interrupting therapy could destabilize mood control unnecessarily.

Migraine prophylaxis is indicated when headache episodes are frequent, prolonged, or significantly impair daily functioning. Preventive therapy aims to reduce the frequency, severity, and duration of migraines rather than treat acute attacks. Medication selection is individualized based on comorbid conditions such as insomnia, anxiety, or chronic tension-type headaches.

Rationale:
A. Butorphanol is an opioid agonist-antagonist used for acute pain management, including severe migraine episodes, but it is not suitable for prophylaxis. Its use carries risks of dependence, sedation, and central nervous system depression. It does not address the underlying neurovascular mechanisms involved in migraine prevention.

B. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine relief due to its inhibition of prostaglandin synthesis. While effective for mild to moderate attacks, it does not prevent the recurrence of migraines. Frequent use may also lead to medication-overuse headaches and gastrointestinal complications, making it inappropriate for prophylactic therapy.

C. Amitriptyline (Elavil) is a tricyclic antidepressant that is effective for migraine prevention, particularly in patients with comorbid insomnia and anxiety. It modulates serotonin and norepinephrine pathways involved in pain perception and central sensitization. Additionally, its sedative properties improve sleep quality, making it especially beneficial for patients with chronic tension headaches and sleep disturbances.

D. Ergotamine is a vasoconstrictive agent used in the acute treatment of migraine attacks, particularly when other therapies are ineffective. It works by stimulating serotonin receptors to reduce intracranial blood vessel dilation. However, it is not used for prophylaxis and carries risks such as rebound headaches and vascular complications with repeated use.